Grifols 2023 Annual Report on Form 20-F Filed With the SEC

Yahoo FinanceApr 19 16:42 ET

Grifols SA - ADR ADR Class B (GRFS) Stock Falls -3.75% This Week; Should You Buy?

Grifols SA - ADR ADR Class B (GRFS) stock is down -35.09% over the last 12 months, and the average rating from Wall Street analysts is a Hold. InvestorsObserver’s proprietary ranking system, gives GRFS stock a score of 30 out of a possible 100. That r

InvestorsObserverFeb 7, 2022 12:19 ET

Should You Add Grifols SA - ADR ADR Class B (GRFS) Stock to Your Portfolio Monday?

Grifols SA - ADR ADR Class B (GRFS) is around the bottom of the Healthcare sector according to InvestorsObserver. GRFS received an overall rating of 3, which means that it scores h

InvestorsObserverJan 31, 2022 12:06 ET

Velanne Asset Management Ltd Buys , Sells Raytheon Technologies Corp, Vistra Corp, Grifols SA

Investment company Velanne Asset Management Ltd (Current Portfolio) buys , sells Raytheon Technologies Corp, Vistra Corp, Grifols SA, The Walt Disney Co, BrightSphere Investment Group Inc during the 3

YahooFinanceAUJan 28, 2022 14:12 ET

Grifols SA - ADR ADR Class B (GRFS) Stock Declines -6.46% This Week; Should You Buy?

Grifols SA - ADR ADR Class B (GRFS) stock is lower by -36.13% over the last 12 months, and the average rating from Wall Street analysts is a Hold. InvestorsObserver’s proprietary ranking system, gives GRFS stock a score of 20 out of a possible 100. Th

InvestorsObserverJan 27, 2022 13:11 ET

Global Myasthenia Gravis Clinical Trials Market Research Report Review, H2 2021 Edition - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Myasthenia Gravis - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides an overview of the

BusinesswireDec 1, 2021 12:00 ET